- Home
- CLRB vs HOTH Comparison
CLRB vs HOTH Comparison
Compare CLRB & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- HOTH
- Stock Information
- Founded
- CLRB 2002
- HOTH 2017
- Country
- CLRB United States
- HOTH United States
- Employees
- CLRB N/A
- HOTH N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- HOTH Health Care
- Exchange
- CLRB Nasdaq
- HOTH Nasdaq
- Market Cap
- CLRB 14.2M
- HOTH 15.6M
- IPO Year
- CLRB N/A
- HOTH 2019
- Fundamental
- Price
- CLRB $5.49
- HOTH $1.75
- Analyst Decision
- CLRB Hold
- HOTH Strong Buy
- Analyst Count
- CLRB 2
- HOTH 3
- Target Price
- CLRB N/A
- HOTH $4.00
- AVG Volume (30 Days)
- CLRB 89.6K
- HOTH 2.1M
- Earning Date
- CLRB 11-17-2025
- HOTH 11-11-2025
- Dividend Yield
- CLRB N/A
- HOTH N/A
- EPS Growth
- CLRB N/A
- HOTH N/A
- EPS
- CLRB N/A
- HOTH N/A
- Revenue
- CLRB N/A
- HOTH N/A
- Revenue This Year
- CLRB N/A
- HOTH N/A
- Revenue Next Year
- CLRB N/A
- HOTH N/A
- P/E Ratio
- CLRB N/A
- HOTH N/A
- Revenue Growth
- CLRB N/A
- HOTH N/A
- 52 Week Low
- CLRB $4.11
- HOTH $0.65
- 52 Week High
- CLRB $67.50
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- CLRB 60.03
- HOTH 75.83
- Support Level
- CLRB $5.05
- HOTH $1.53
- Resistance Level
- CLRB $5.34
- HOTH $1.87
- Average True Range (ATR)
- CLRB 0.34
- HOTH 0.15
- MACD
- CLRB 0.07
- HOTH 0.05
- Stochastic Oscillator
- CLRB 98.15
- HOTH 95.53
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).